FDA Approves Natco’s Generic Bendamustine HCL Powder

Natco Pharma has announced that it has received FDA approval to produce a generic version of Bendamustine Hydrochloride powder for injection. Natco is working with its marketing partner, Breckenridge Pharmaceutical, to launch the drug on November 1, 2019. Natco and Breckenridge are expected to share 180 day exclusivity with other ANDA first filers.

Read the source article at the Business Standard